Pictet-Biotech HR AUD

Reference Data

ISIN LU2353392348
Valor Number 112071796
Bloomberg Global ID
Fund Name Pictet-Biotech HR AUD
Fund Provider Pictet Asset Management S.A. Genève, Switzerland
Phone: +41 58 323 10 24
www.assetmanagement.pictet
Fund Provider Pictet Asset Management S.A.
Representative in Switzerland Pictet Asset Management S.A.
Genève 73
Phone: +41 58 323 30 00
Distributor(s) Credit Suisse AG
Zürich
Phone: +41 44 333 11 11 UBS AG
Zürich
Phone: +41 44 234 11 11 Vontobel Fonds Services AG
Zürich
Phone: +41 58 283 74 77
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** To increase the value of your investment while seeking to achieve a positive social impact. The Fund applies a sustainable strategy and invests at least two-thirds of its net assets in equities or similar securities issued by biopharmaceutical companies throughout the world. Companies supporting the health of people with high innovation capacity. Better therapies can deliver true value to patients and healthcare systems alike. These companies are tackling high unmet medical needs and reduce the pressures on healthcare budgets through the reduction of hospital admissions or symptom management. The Fund invests mainly in companies whose significant proportion of their activities are related to, but not limited to, new mechanisms of actions offering potential cures or management of diseases that were hard to treat before, technology platforms, research tools and services in the biotechnology value chain as well as the improvement of therapies or drugs.
Peculiarities

Fund Prices

Current Price * 643.51 AUD 03.04.2025
Previous Price * 638.46 AUD 02.04.2025
52 Week High * 853.66 AUD 16.07.2024
52 Week Low * 638.46 AUD 02.04.2025
NAV * 643.51 AUD 03.04.2025
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 1,930,791,088
Unit/Share Assets *** 346,444
Trading Information SIX

Performance

YTD Performance -11.01% 31.12.2024
03.04.2025
YTD Performance (in CHF) -12.56% 31.12.2024
03.04.2025
1 month -11.01% 03.03.2025
03.04.2025
3 months -12.58% 03.01.2025
03.04.2025
6 months -17.97% 03.10.2024
03.04.2025
1 year -14.42% 04.04.2024
03.04.2025
2 years -1.31% 03.04.2023
03.04.2025
3 years -7.96% 04.04.2022
03.04.2025
5 years -28.68% 22.06.2021
03.04.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Gilead Sciences Inc 6.57%
Insmed Inc 5.17%
argenx SE ADR 4.87%
Regeneron Pharmaceuticals Inc 3.55%
SpringWorks Therapeutics Inc Ordinary Shares 3.08%
Sarepta Therapeutics Inc 3.07%
Alnylam Pharmaceuticals Inc 3.03%
Amgen Inc 2.94%
TG Therapeutics Inc 2.86%
Vaxcyte Inc Ordinary Shares 2.83%
Last data update 28.02.2025

Cost / Risk

TER *** 2.75%
TER date *** 30.09.2024
Performance Fee ***
PTR
Max. Management Fee *** 2.90%
Ongoing Charges *** 2.75%
SRRI ***
SRRI date *** 31.07.2021

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)